Abstract
Objective: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), in a follow up to the main Cannabinoids in Multiple Sclerosis (CAMS) study.
Methods: In total, 630 patients with stable MS with muscle spasticity from 33 UK centres were randomised to receive oral Δ9-tetrahydrocannabinol (Δ9-THC), cannabis extract, or placebo in the main 15 week CAMS study. The primary outcome was change in the Ashworth spasticity scale. Secondary outcomes were the Rivermead Mobility Index, timed 10 metre walk, UK Neurological Disability Score, postal Barthel Index, General Health Questionnaire-30, and a series of nine category rating scales. Following the main study, patients were invited to continue medication, double blinded, for up to12 months in the follow up study reported here.
Results: Intention to treat analysis of data from the 80% of patients followed up for 12 months showed evidence of a small treatment effect on muscle spasticity as measured by change in Ashworth score from baseline to 12 months (Δ9-THC mean reduction 1·82 (n = 154, 95% confidence interval (CI) 0.53 to 3.12), cannabis extract 0.10 (n = 172, 95% CI –0.99 to 1.19), placebo –0.23 (n = 176, 95% CI –1.41 to 0.94); p = 0.04 unadjusted for ambulatory status and centre, p = 0.01 adjusted). There was suggestive evidence for treatment effects of Δ9-THC on some aspects of disability. There were no major safety concerns. Overall, patients felt that these drugs were helpful in treating their disease.
Conclusions: These data provide limited evidence for a longer term treatment effect of cannabinoids. A long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.
Full Text
The Full Text of this article is available as a PDF (94.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997;38(1):44–48. doi: 10.1159/000112901. [DOI] [PubMed] [Google Scholar]
- Hampson A. J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268–8273. doi: 10.1073/pnas.95.14.8268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001 Oct 4;413(6855):527–531. doi: 10.1038/35097089. [DOI] [PubMed] [Google Scholar]
- Pryce Gareth, Ahmed Zubair, Hankey Deborah J. R., Jackson Samuel J., Croxford J. Ludovic, Pocock Jennifer M., Ledent Catherine, Petzold Axel, Thompson Alan J., Giovannoni Gavin. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003 Jul 22;126(Pt 10):2191–2202. doi: 10.1093/brain/awg224. [DOI] [PubMed] [Google Scholar]
- Skaper S. D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3984–3989. doi: 10.1073/pnas.93.9.3984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stocchi Fabrizio, Olanow C. Warren. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol. 2003;53 (Suppl 3):S87–S99. doi: 10.1002/ana.10488. [DOI] [PubMed] [Google Scholar]
- Wiles C. M., Newcombe R. G., Fuller K. J., Shaw S., Furnival-Doran J., Pickersgill T. P., Morgan A. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):174–179. doi: 10.1136/jnnp.70.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zajicek John, Fox Patrick, Sanders Hilary, Wright David, Vickery Jane, Nunn Andrew, Thompson Alan, UK MS Research Group Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517–1526. doi: 10.1016/S0140-6736(03)14738-1. [DOI] [PubMed] [Google Scholar]